Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘.Delay in Quick Shot Testosterone Clinical Trials’

Delay in Quick Shot Testosterone Clinical Program is Not a Major Setback for the Stock (ATRS, Buy, $2.53)

Antares sent out a press release today¬†about a new development in the Quick Shot Testosterone phase 3 program. The Company said that based on a single reported occurrence of hives in the completed phase 2 study, which the FDA characterized as an apparent allergic reaction. The agency ¬†is recommending that the Company create a larger […]